Form 4: Utah Medical Products Inc. Executive Acquires Stock Options

Brian Koopman, Principal Financial Officer of Utah Medical Products Inc., reports the acquisition of stock options.

Summary

• On November 1, 2024, Brian Koopman, the Principal Financial Officer of Utah Medical Products Inc., acquired 500 employee stock options.
• The exercise price of these options is $64.09.
• The options vest in installments, starting with 25% on October 1, 2025, and then an additional 6.25% on January 1, 2026, and the first day of each calendar quarter thereafter.
• The options are fully exercisable on October 1, 2028, and expire on November 1, 2034.
• Following this transaction, Koopman directly owns 5,100 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own. The grant could be seen as a positive sign of confidence, but it's also a routine part of executive compensation.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the compensation and equity ownership of key executives.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the medical device industry.
• Vesting schedules and exercise prices are typically structured to align executive incentives with long-term shareholder value creation.
• Companies like Medtronic, Stryker, and Boston Scientific also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as an incentive for the executive to improve company performance.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates